---
schema_version: "secwatch.filing_event.v1"
accession: "0000927653-25-000121"
form_type: "8-K"
ticker: "MCK"
cik: "0000927653"
company_name: "MCKESSON CORP"
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:19:36.446631+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# McKesson reorganizes into 4 segments; restates FY2025 revenue of $359B under new structure

## Summary
- Starting Q2 FY2026, McKesson will report 4 segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions.
- FY2025 restated revenue: North American Pharm $304.5B, Oncology & Multispecialty $36.9B, Prescription Tech $5.2B, Medical-Surgical $11.4B; total $359.1B.
- FY2025 restated adjusted op. profit: N.A. Pharm $3,145M (1.03%), Oncology & Multispecialty $936M (2.54%), Prescription Tech $961M (18.42%), Med-Surg $1,022M (8.98%).
- Agreement to sell Norway operations signed Aug 4, 2025 (subject to regulatory approval); also intends to separate Medical-Surgical Solutions (announced May 2025).
- Segment changes did not impact previously issued consolidated financials or EPS.

## SEC filing metadata
- accession: 0000927653-25-000121
- form_type: 8-K
- ticker: MCK
- cik: 0000927653
- company_name: MCKESSON CORP
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/927653/000092765325000121/0000927653-25-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/927653/000092765325000121/mck-20250918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000927653-25-000121
- JSON: https://secwatch.observer/filing/0000927653-25-000121.json
- Plain text: https://secwatch.observer/filing/0000927653-25-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.